Target Name: CDH13
NCBI ID: G1012
Review Report on CDH13 Target / Biomarker Content of Review Report on CDH13 Target / Biomarker
CDH13
Other Name(s): Cadherin 13, H-cadherin (heart) | heart cadherin | H-cadherin (heart) | Truncated-cadherin | Cadherin-13 (isoform 1) | CDHH | Cadherin 13, transcript variant 2 | Heart cadherin | Cadherin-13 (isoform 2) | P105 | Truncated cadherin | CDH13 variant 1 | Cadherin 13, transcript variant 1 | T-cadherin | Heart-cadherin | CAD13_HUMAN | T-Cadherin (CDH13) | T-cad | CDH13 variant 2 | H-cadherin | cadherin 13, H-cadherin (heart) | Cadherin-13 | cadherin 13

CDH13: A Potential Drug Target and Biomarker for the Treatment of Cardiovascular Disease

Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, placing a significant burden on healthcare systems. The identification of potential drug targets and biomarkers for the treatment of CVD remains a major focus in the pharmaceutical industry and academic research. One promising candidate for drug development is CDH13, a gene that has been identified as a potential drug target and biomarker for the treatment of CVD.

CDH13: The gene and its function

CDH13 is a gene that encodes a protein known as CDH13. The protein is expressed in the heart and has been shown to play a critical role in the development and progression of CVD. CDH13 has been shown to promote the formation of foam cells, a type of aberrant cell that can contribute to the development of cardiovascular disease.

In addition to its role in the formation of foam cells, CDH13 has also been shown to play a role in the regulation of cell proliferation and survival. Studies have shown that CDH13 can inhibit the growth of cancer cells and promote the growth of healthy cardiac cells.

CDH13 as a potential drug target

The identification of CDH13 as a potential drug target is based on its ability to promote the formation of foam cells and its potential role in the regulation of cell proliferation and survival. Researchers are exploring the use of drugs that can modulate the expression of CDH13 to treat CVD.

One approach to targeting CDH13 is the use of small molecules that can inhibit its activity. Researchers have identified a number of small molecules that have been shown to inhibit the formation of foam cells and improve the growth of healthy cardiac cells. These small molecules are now being tested for use in the treatment of CVD.

CDH13 as a biomarker

In addition to its potential as a drug target, CDH13 has also been identified as a potential biomarker for the diagnosis and prognosis of CVD. Studies have shown that the expression of CDH13 is significantly elevated in the hearts of individuals who have experienced a cardiovascular event, such as a heart attack or stroke.

The identification of CDH13 as a potential biomarker for CVD has significant implications for the development of diagnostic tests and therapies for CVD. By identifying biomarkers that can be used to diagnose and prognosis CVD, researchers may be able to develop more accurate and effective therapies for this debilitating condition.

Conclusion

CDH13 is a promising candidate for drug development as a potential drug target and biomarker for the treatment of CVD. The identification of CDH13 as a potential drug target and biomarker has significant implications for the development of new therapies for this debilitating condition. Further research is needed to fully understand the role of CDH13 in the development and progression of CVD, as well as its potential as a biomarker for the diagnosis and prognosis of CVD.

Protein Name: Cadherin 13

Functions: Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. May act as a negative regulator of neural cell growth

The "CDH13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CDH13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CDH13-AS2 | CDH15 | CDH16 | CDH17 | CDH18 | CDH19 | CDH2 | CDH20 | CDH22 | CDH23 | CDH24 | CDH26 | CDH3 | CDH4 | CDH5 | CDH6 | CDH7 | CDH8 | CDH9 | CDHR1 | CDHR18P | CDHR2 | CDHR3 | CDHR4 | CDHR5 | CDIN1 | CDIP1 | CDIPT | CDIPTOSP | CDK1 | CDK10 | CDK11A | CDK11B | CDK12 | CDK13 | CDK14 | CDK15 | CDK16 | CDK17 | CDK18 | CDK19 | CDK2 | CDK20 | CDK2AP1 | CDK2AP2 | CDK2AP2P2 | CDK2AP2P3 | CDK3 | CDK4 | CDK5 | CDK5R1 | CDK5R2 | CDK5RAP1 | CDK5RAP2 | CDK5RAP3 | CDK6 | CDK6-AS1 | CDK7 | CDK8 | CDK9 | CDKAL1 | CDKL1 | CDKL2 | CDKL3 | CDKL4 | CDKL5 | CDKN1A | CDKN1B | CDKN1C | CDKN2A | CDKN2A-DT | CDKN2AIP | CDKN2AIPNL | CDKN2AIPNLP1 | CDKN2B | CDKN2B-AS1 | CDKN2C | CDKN2D | CDKN3 | CDNF | CDO1 | CDON | CDPF1 | CDR1 | CDR2 | CDR2L | CDRT15 | CDRT15L2 | CDRT4 | CDRT7 | CDS1 | CDS2 | CDSN | CDT1 | CDV3 | CDX1 | CDX2 | CDX4 | CDY1 | CDY1B